SANTA CRUZ BIOTECHNOLOGY, INC.

C6 (3G11): sc-66191

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

The complement cascade is a multi-protein system that functions to clear pathogens from an infected host. Part of the innate (unchanging) immune system, the complement cascade consists of proteins and inactive zymogens that are present in blood and are stimulated by one of several triggers. Once stimulated, the cascade relays amplified responses throughout the body, ultimately activating the cell-killing membrane attack complex which can insert itself into the cell membrane and cause the cell to lyse. C6 (Complement component C6) is a 934 amino acid secreted protein that plays a role in the complement cascade, specifically functioning as part of the membrane attack complex. Expressed as two transcript variants, C6 contains one EGF-like domain, one LDL-receptor class A domain, one MACPF domain, two Sushi domains and three TSP type-1 domains. C6 deficiency is correlated with a higher risk of bacterial infection, further supporting the importance of C6 in the innate immune system.

REFERENCES

1. DiScipio, R.G., et al. 1989. The molecular architecture of human complement component C6. J. Biol. Chem. 264: 16197-16206.
2. Haefliger, J.A., et al. 1989. Complete primary structure and functional characterization of the sixth component of the human complement system. Identification of the C5b-binding domain in complement C6. J. Biol. Chem. 264: 18041-18051.
3. Hobart, M.J., et al. 1993. Structure of the human C6 gene. Biochemistry 32: 6198-6205.
4. González, S., et al. 1996. Characterization of the human C6 promoter: requirement of the CCAAT enhancer binding protein binding site for C6 gene promoter activity. J. Immunol. 157: 2282-2290.
5. Chamberlain-Banoub, J., et al. 2006. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin. Exp. Immunol. 146: 278-286.
6. Qian, Z., et al. 2006. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation 82: 857-864.
7. Fischetti, F., et al. 2007. Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum. 56: 1187-1197.
8. Liu, E., et al. 2007. Re-establishment of complement C6-deficient rabbit colony by cryopreserved sperm transported from abroad. Exp. Anim. 56: 167-171.
9. Parham, K.L., et al. 2007. Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family. Mol. Immunol. 44: 2756-2760.

CHROMOSOMAL LOCATION

Genetic locus: C6 (mouse) mapping to 15 A1.

SOURCE

C6 (3G11) is a mouse monoclonal antibody raised against purified C6 of rat origin.

PRODUCT

Each vial contains 200 µg IgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

C6 (3G11) is recommended for detection of C6 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Suitable for use as control antibody for C6 siRNA (m): sc-72770, C6 shRNA Plasmid (m): sc-72770-SH and C6 shRNA (m) Lentiviral Particles: sc-72770-V.

Molecular Weight of C6: 120 kDa.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.